[{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"bb6fe11c-92d7-43aa-a535-cfa2d75b128c","acronym":"CNS-PHLAT","url":"https://clinicaltrials.gov/study/NCT06687772","created_at":"2025-02-25T19:05:14.187Z","updated_at":"2025-02-25T19:05:14.187Z","phase":"Phase 2","brief_title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","source_id_and_acronym":"NCT06687772 - CNS-PHLAT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • melphalan • thiotepa"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/16/2025","start_date":" 01/16/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-01-22"},{"id":"ea7e7be5-dd5d-4509-9884-da4eb277aa63","acronym":"P+R-ICE","url":"https://clinicaltrials.gov/study/NCT05221645","created_at":"2022-02-05T18:29:06.759Z","updated_at":"2025-02-25T16:17:16.628Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05221645 - P+R-ICE","lead_sponsor":"University of Southampton","biomarkers":" CD20","pipe":" | ","alterations":" CD34 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 06/27/2022","start_date":" 06/27/2022","primary_txt":" Primary completion: 05/30/2026","primary_completion_date":" 05/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-05"},{"id":"0e15a431-fa68-4600-8321-5e50101e95ba","acronym":"EATL-001","url":"https://clinicaltrials.gov/study/NCT03217643","created_at":"2021-01-18T15:52:35.192Z","updated_at":"2025-02-25T14:50:36.812Z","phase":"Phase 2","brief_title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","source_id_and_acronym":"NCT03217643 - EATL-001","lead_sponsor":"Imagine Institute","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • carmustine"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2024-06-19"},{"id":"7026c02a-02d2-4eaf-9842-da3071018ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02443077","created_at":"2021-01-18T11:42:20.749Z","updated_at":"2024-07-02T16:34:37.048Z","phase":"Phase 3","brief_title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02443077","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1","pipe":" | ","alterations":" CD79A mutation + CD79B mutation","tags":["MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 05/10/2025","primary_completion_date":" 05/10/2025","study_txt":" Completion: 05/10/2025","study_completion_date":" 05/10/2025","last_update_posted":"2024-06-07"},{"id":"48a0919b-3b83-483a-ac34-75efef034744","acronym":"","url":"https://clinicaltrials.gov/study/NCT01476839","created_at":"2021-01-18T06:09:44.020Z","updated_at":"2024-07-02T16:35:14.031Z","phase":"Phase 1","brief_title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","source_id_and_acronym":"NCT01476839","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/09/2012","start_date":" 11/09/2012","primary_txt":" Primary completion: 07/24/2021","primary_completion_date":" 07/24/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"ba959a30-fc13-41fa-bfe2-ed5b6c5cbb41","acronym":"","url":"https://clinicaltrials.gov/study/NCT02342782","created_at":"2021-01-18T11:08:11.471Z","updated_at":"2024-07-02T16:35:14.106Z","phase":"Phase 1","brief_title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02342782","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • CD34","pipe":"","alterations":" ","tags":["ALK • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • etoposide oral • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"5f5a65f2-c9f4-4073-a80b-3cfdbd4c58d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382977","created_at":"2021-01-18T16:41:38.687Z","updated_at":"2024-07-02T16:35:14.613Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","source_id_and_acronym":"NCT03382977","lead_sponsor":"VBI Vaccines Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • carmustine • VBI-1901"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-15"},{"id":"d8a4d573-54c5-44f7-aa60-0be67e158582","acronym":"LYMA-101","url":"https://clinicaltrials.gov/study/NCT02896582","created_at":"2021-01-18T14:12:53.282Z","updated_at":"2024-07-02T16:35:14.422Z","phase":"Phase 2","brief_title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","source_id_and_acronym":"NCT02896582 - LYMA-101","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression • CCND1 expression","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cytarabine • Gazyva (obinutuzumab) • etoposide IV • dexamethasone • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-15"},{"id":"70b78002-ce17-4480-b925-f69956c3deca","acronym":"hSTAR GBM","url":"https://clinicaltrials.gov/study/NCT05052957","created_at":"2021-09-22T11:53:36.877Z","updated_at":"2024-07-02T16:35:17.535Z","phase":"Phase 2","brief_title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","source_id_and_acronym":"NCT05052957 - hSTAR GBM","lead_sponsor":"Leland Metheny","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH2 mutation • IDH wild-type • MGMT expression","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH wild-type • MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-28"},{"id":"6021e506-3657-4f55-8fd6-b08df8a6de52","acronym":"","url":"https://clinicaltrials.gov/study/NCT00641381","created_at":"2021-01-18T02:23:14.117Z","updated_at":"2024-07-02T16:35:18.035Z","phase":"Phase 1","brief_title":"Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","source_id_and_acronym":"NCT00641381","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • carmustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/10/2000","start_date":" 05/10/2000","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-02-22"},{"id":"4e9aa552-a12c-4da8-8240-a354eef4c428","acronym":"","url":"https://clinicaltrials.gov/study/NCT00968760","created_at":"2021-01-18T03:46:34.880Z","updated_at":"2024-07-02T16:35:25.752Z","phase":"Phase 1","brief_title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","source_id_and_acronym":"NCT00968760","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Proleukin (aldesleukin) • Depocyte (liposomal cytarabine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 04/23/2020","primary_completion_date":" 04/23/2020","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2023-12-19"},{"id":"14c3454a-5919-4954-b349-704871746288","acronym":"","url":"https://clinicaltrials.gov/study/NCT05540340","created_at":"2022-09-14T17:55:35.016Z","updated_at":"2024-07-02T16:35:26.679Z","phase":"","brief_title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","source_id_and_acronym":"NCT05540340","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • carmustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-11"},{"id":"d2f28e68-db4b-42b9-85cb-b34ffca07748","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125642","created_at":"2021-01-18T15:23:59.295Z","updated_at":"2024-07-02T16:35:30.655Z","phase":"Phase 2","brief_title":"Auto Stem Cell Transplant for Lymphoma Patients","source_id_and_acronym":"NCT03125642","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" ALK • CD4 • TCL1A","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD4 • TCL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/20/2017","start_date":" 04/20/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-11-02"},{"id":"5ef621d3-f9a5-4748-be55-deaada2d28a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574509","created_at":"2021-01-18T02:05:53.111Z","updated_at":"2024-07-02T16:35:34.087Z","phase":"Phase 1","brief_title":"Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00574509","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/04/1996","start_date":" 03/04/1996","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 12/10/2014","study_completion_date":" 12/10/2014","last_update_posted":"2023-10-10"},{"id":"fcb330ce-34f3-4958-8a53-be2270f787e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01035463","created_at":"2021-01-18T04:03:56.430Z","updated_at":"2024-07-02T16:35:34.269Z","phase":"Phase 1/2","brief_title":"Lenalidomide Therapy After Chemotherapy \u0026 Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01035463","lead_sponsor":"University of Nebraska","biomarkers":" ALK • CD34","pipe":" | ","alterations":" ALK negative","tags":["ALK • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • cytarabine • etoposide IV • carmustine • melphalan • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 11/12/2009","start_date":" 11/12/2009","primary_txt":" Primary completion: 07/27/2017","primary_completion_date":" 07/27/2017","study_txt":" Completion: 07/27/2018","study_completion_date":" 07/27/2018","last_update_posted":"2023-10-09"},{"id":"f7e16369-1429-45d8-9dba-024985674f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00080886","created_at":"2021-01-18T00:13:28.893Z","updated_at":"2024-07-02T16:35:34.490Z","phase":"Phase 2","brief_title":"Rituximab, Carmustine; Cytarabine, Etoposide, \u0026 Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00080886","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Gliadel Wafer (carmustine implant) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/08/2002","start_date":" 05/08/2002","primary_txt":" Primary completion: 11/01/2005","primary_completion_date":" 11/01/2005","study_txt":" Completion: 03/12/2015","study_completion_date":" 03/12/2015","last_update_posted":"2023-10-06"},{"id":"101d70a0-c1f6-4211-98a4-0d14c8ef1bf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00571493","created_at":"2021-01-18T02:05:12.451Z","updated_at":"2025-02-25T14:54:50.414Z","phase":"Phase 1/2","brief_title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","source_id_and_acronym":"NCT00571493","lead_sponsor":"University of Nebraska","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • etoposide IV • carmustine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 04/14/2006","start_date":" 04/14/2006","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2023-09-28"},{"id":"2212a595-3764-4cbc-b733-3f7990d38019","acronym":"","url":"https://clinicaltrials.gov/study/NCT00572013","created_at":"2021-01-18T02:05:18.130Z","updated_at":"2024-07-02T16:35:37.720Z","phase":"Phase 1/2","brief_title":"Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma","source_id_and_acronym":"NCT00572013","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • carmustine"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 05/12/1998","start_date":" 05/12/1998","primary_txt":" Primary completion: 01/01/2001","primary_completion_date":" 01/01/2001","study_txt":" Completion: 09/18/2009","study_completion_date":" 09/18/2009","last_update_posted":"2023-09-07"},{"id":"122d2eb4-6851-4d2e-9c39-e9da079bd81b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00007852","created_at":"2021-01-17T23:54:22.562Z","updated_at":"2024-07-02T16:35:38.248Z","phase":"Phase 2","brief_title":"Rituximab \u0026 Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00007852","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 09/01/2000","start_date":" 09/01/2000","primary_txt":" Primary completion: 01/01/2002","primary_completion_date":" 01/01/2002","study_txt":" Completion: 01/01/2011","study_completion_date":" 01/01/2011","last_update_posted":"2023-09-01"},{"id":"46e4deaa-8f21-4cac-8410-39826ed5483d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006695","created_at":"2021-01-17T23:54:05.754Z","updated_at":"2024-07-02T16:35:38.269Z","phase":"Phase 2","brief_title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00006695","lead_sponsor":"University of Nebraska","biomarkers":" CD20 • CD34","pipe":"","alterations":" ","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2000","start_date":" 04/01/2000","primary_txt":" Primary completion: 09/01/2005","primary_completion_date":" 09/01/2005","study_txt":" Completion: 12/16/2014","study_completion_date":" 12/16/2014","last_update_posted":"2023-09-01"},{"id":"560b05c1-dc9c-49ef-a0d1-2bdc461a1ab3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02797470","created_at":"2021-01-18T13:43:28.094Z","updated_at":"2024-07-02T16:35:41.470Z","phase":"Phase 1/2","brief_title":"Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant","source_id_and_acronym":"NCT02797470","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" ALK • CD4","pipe":" | ","alterations":" ALK positive","tags":["ALK • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/23/2016","start_date":" 06/23/2016","primary_txt":" Primary completion: 05/13/2021","primary_completion_date":" 05/13/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-01"},{"id":"c13bf7f2-7d71-4a67-ac7d-1ce03f5aeb55","acronym":"","url":"https://clinicaltrials.gov/study/NCT05931263","created_at":"2023-07-05T14:08:35.001Z","updated_at":"2024-07-02T16:35:43.965Z","phase":"Phase 3","brief_title":"A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL","source_id_and_acronym":"NCT05931263","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Epidaza (chidamide) • carmustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-07-04"}]